Benefits
Sustained energy without tolerance
An 8-week RCT (n=60) at 200 mg or 300 mg daily demonstrated no tachyphylactic response — energy, focus, concentration, motivation, and mood benefits remained stable across 8 weeks of continuous daily use, in direct contrast to caffeine's known tolerance development pattern. This is theorized to reflect TeaCrine®'s distinct receptor activity profile vs caffeine.
Mood and motivation enhancement
Theacrine engages dopaminergic pathways (D1 and D2 receptors) alongside adenosine inhibition — providing motivational and mood effects beyond caffeine alone. Pilot studies report increased subjective energy, reduced fatigue, improved concentration and motivation, and reduced anxiety at typical clinical doses (200 mg). Animal models also show antidepressant-like effects via hippocampal neurogenesis pathways.
Caffeine synergy and extended duration
Co-ingestion of TeaCrine® with caffeine significantly increases TeaCrine® plasma exposure (Cmax and AUC) compared to TeaCrine® alone — a pharmacokinetic synergy. The combination has shown greater cognitive benefits than either supplement alone in soccer player and tactical personnel trials. TeaCrine®'s naturally long half-life (~26 hours vs caffeine's ~6 hours) provides extended-duration effects without caffeine's shorter peak-and-crash pattern.
No cardiovascular side effects at clinical doses
Across the Bloomer 2015 acute crossover (TeaCrine® + caffeine) and Taylor 2016 8-week safety study (TeaCrine® 200–300 mg), TeaCrine® showed no significant impact on heart rate, blood pressure, lipid profiles, or other safety markers — unlike caffeine which reliably increases blood pressure and heart rate. This makes TeaCrine® particularly suitable for users sensitive to caffeine's cardiovascular effects.
Mechanism of action
Dual adenosine and dopamine pathway modulation
Theacrine inhibits adenosine A1 and A2A receptors (blocking fatigue signals) like caffeine, but additionally activates dopamine D1 and D2 receptors — triggering motivation, reward, and mood circuits that caffeine does not engage. This dual action explains TeaCrine's distinct experiential profile.
Non-habituating receptor activity
Unlike caffeine, which produces tolerance through adenosine receptor upregulation with chronic use, theacrine's distinct binding pattern at adenosine A1/A2A receptors (and possibly partial agonism at some sites) appears to avoid this upregulation mechanism. The 8-week Taylor 2016 trial confirmed no tachyphylaxis at doses up to 300 mg/day, supporting the non-habituating clinical profile.
Enhanced bioavailability with caffeine co-administration
Co-ingestion with caffeine significantly increases TeaCrine plasma AUC and Cmax in humans — likely through caffeine's inhibition of CYP1A2 metabolism. This pharmacokinetic synergy means lower effective doses of TeaCrine when combined with caffeine.
Clinical trials
Randomized, double-blind, three-condition crossover trial comparing TheaTrim (containing TeaCrine® + 150 mg caffeine) vs. caffeine alone (150 mg) vs. placebo in 20 healthy young adults, with cognitive and hemodynamic assessments over 4 hours post-dose. (Kuhman/Bloomer 2015)
20 healthy young adults (10 men, 10 women, ages 20–22). Three test days separated by approximately one week.
Both TheaTrim and caffeine showed trends toward improved cognitive performance (Trail Making Test, Digit Symbol Substitution Test, reaction time) with no statistically significant differences between conditions. Subjective energy and mood improved with both active conditions. No significant effects on heart rate or blood pressure with TeaCrine®, in contrast to caffeine's known cardiovascular effects.
Randomized, placebo-controlled trial of TeaCrine® at 200 mg/day or 300 mg/day vs. placebo in 60 healthy adults for 8 weeks of continuous daily use. Examined safety markers (heart rate, blood pressure, lipid profiles, hematology, liver/kidney/immune function) and tachyphylaxis. (Taylor et al. 2016)
60 healthy men and women (mean age 22.5 years). 8-week daily supplementation.
TeaCrine® showed clinical safety with no significant changes in any safety markers (vital signs, blood chemistry, hematology) at 200 or 300 mg/day. Critically, no tachyphylactic response was observed across 8 weeks — energy, focus, motivation, and mood benefits remained stable, in contrast to caffeine's known tolerance pattern.
Randomized, four-condition crossover trial comparing TeaCrine® alone, caffeine alone, TeaCrine® + caffeine, and placebo on cognitive performance and time-to-exhaustion (TTE) during a 90-minute simulated soccer match in 24 high-level soccer players. (Bello et al. 2019)
24 high-level male and female soccer players (mean age 21, VO2max ~50–55 mL/kg/min). Four randomized conditions.
TeaCrine® alone produced 27–38% improvements in time-to-exhaustion. The TeaCrine® + caffeine combination provided greater cognitive benefits (reaction time, choice reaction, cognitive load tasks) than either supplement alone, suggesting synergy on cognitive performance under physical load.